Crizotinib and lorlatinib both target ALK and have significant inhibitory effects on ALK‐positive lung cancer cells,14 however, lorlatinib is better at crossing the blood brain barrier (BBB), improving intracranial disease control.15 The gene discussed is ALK; the disease is lung cancer.